June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Intraocular pressure fluctuation and rates of visual field progression in primary open-angle glaucoma: an exploratory analysis from the United Kingdom Glaucoma Treatment Study (UKGTS).
Author Affiliations & Notes
  • Alessandro Rabiolo
    NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, United Kingdom
  • Giovanni Montesano
    NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, United Kingdom
    Optometry and Visual Sciences, City University of London, London, London, United Kingdom
  • David P. Crabb
    Optometry and Visual Sciences, City University of London, London, London, United Kingdom
  • David F Garway-Heath
    NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, United Kingdom
  • Footnotes
    Commercial Relationships   Alessandro Rabiolo None; Giovanni Montesano CenterVue SpA, Ivantis Inc, Code C (Consultant/Contractor); David Crabb Allergan, Apellis, CenterVue, Thea, Roche, Code C (Consultant/Contractor), Santen, Allergan, Apellis, CenterVue, Code F (Financial Support), Santen, Medisoft, Code C , Code S (non-remunerative); David Garway-Heath Allergan, Genentech, Janssen, Novartis, Omikron, Roche, Santen, Code C (Consultant/Contractor), Alcon Research Institute, Janssen, Santen, Code F (Financial Support)
  • Footnotes
    Support  unrestricted investigator-initiated research grant from Pfizer
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 1268 – A0408. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alessandro Rabiolo, Giovanni Montesano, David P. Crabb, David F Garway-Heath; Intraocular pressure fluctuation and rates of visual field progression in primary open-angle glaucoma: an exploratory analysis from the United Kingdom Glaucoma Treatment Study (UKGTS).. Invest. Ophthalmol. Vis. Sci. 2022;63(7):1268 – A0408.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The role of intraocular pressure (IOP) fluctuation in glaucoma progression remains controversial. We investigate whether IOP fluctuation is independently associated with the rate of visual field (VF) progression.

Methods : Participants from the UKGTS with ≥5 VFs were included. Associations between IOP metrics and the mean deviation (MD) rate of progression (RoP) were tested with mixed models. The variables of interest were mean ocular pulse amplitude (OPA), and standard deviation (SD) of diurnal IOP (diurnal fluctuation) and of IOP at all visits (long-term fluctuation). The effect of correlated IOP metrics (Fig1) and multicollinearity were controlled with a principal component analysis of peak and mean IOP during the trial, and baseline (untreated) IOP. The first principal component (PC1) was included as a model covariate. Interactions between variables of interest and time from baseline modelled the variables’ effect on the RoP. Analyses were conducted separately in the two arms.

Results : 213 patients in the placebo arm (mean±SD age: 66.5±10.3 years) and 217 patients in the treatment arm (mean±SD age: 65.2±10.4 years) were included. The median [IQR] of mean IOP, diurnal and long-term fluctuation were, respectively, 18.4 [16.0-21.9], 1.4 [0.9-2.0] and 2.1 [1.6-2.9] mmHg in the placebo arm, and 15.2 [13.2-17.1], 1.3 [0.8-1.7] and 1.9 [1.4-2.6] mmHg in the treatment arm. Mean±SD RoP were -0.32±0.65 and 0.03±0.58 dB/year in the placebo and treatment group, respectively. In the univariable analysis, diurnal and long-term IOP fluctuations were significantly associated with RoP in the placebo arm (p<0.001), and long-term fluctuation in the treatment arm (p=0.047). PC1, combining information of baseline, mean and peak IOPs, were significantly associated with RoP in the placebo (p=0.029) but not in the treatment arm (p=0.95). In the multivariable model, diurnal (placebo estimate: 0.047 dB/year, p=0.60; treatment estimate: 0.046 dB/year, p=0.63) and long-term IOP fluctuations (placebo estimate: -0.124 dB/year, p=0.16; treatment estimate: -0.119 dB/year, p=0.63) were not significantly associated with the RoP (Fig2). OPA was also not associated with RoP (p≥0.11).

Conclusions : This study confirms that IOP fluctuation is not an independent factor for glaucoma progression and other aspects of IOP may be more informative.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×